On the absorption of alendronate in rats.
Alendronate is an antiosteolytic agent under investigation for the treatment of a number of bone disorders. Since the compound is a zwitterion with five pKa values and is completely ionized in the intestine at the physiological pH, absorption is poor; less than 1% of an oral dose is available systemically in rats. In the present studies, absorption was found to be predominantly in the upper part of the small intestine. Administration of buffered solutions of alendronate (pH 2-11) did not improve absorption. Whereas food markedly impaired the absorption of alendronate, EDTA enhanced absorption in a dose-dependent manner. Pretreatment of rats with ulcerogenic agents, mepirizole, acetylsalicylic acid, or indomethacin, resulted in a 3-7-fold increase in the oral absorption of alendronate. The absorption of phenol red, added as an indicator of intestinal tissue damage, was also increased in rats with experimental peptic ulcers. The enhanced absorption of alendronate observed in rats with experimental peptic ulcers was attributed to the alteration of the integrity of the intestinal membrane.
Lin
J H
JH
Merck Research Laboratories, West Point, Pennsylvania 19486.
Chen
I W
IW
deLuna
F A
FA
D000284:Administration, Oral; D019386:Alendronate; D000818:Animals; D001842:Bone and Bones / Q000378:metabolism; D002250:Carbon Radioisotopes; D004064:Digestive System / Q000378:metabolism; D004164:Diphosphonates / Q000097:blood / Q000493:pharmacokinetics*; D004492:Edetic Acid / Q000494:pharmacology; D005772:Gastrointestinal Transit / Q000502:physiology; D005947:Glucose / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D008297:Male; D010437:Peptic Ulcer / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D002250:Carbon Radioisotopes; D004164:Diphosphonates; D004492:Edetic Acid; D005947:Glucose; D019386:Alendronate